Curocell Overview
- Year Founded
-
2017
- Status
-
Public
- Employees
-
140
- Stock Symbol
-
372320
- Investments
-
1
- Share Price
-
$16.71
- (As of Friday Closing)
Curocell General Information
Description
Curocell Inc is engaged in medical and pharmaceutical research and development. The company is into development of CAR-T treatments that enhance the natural function of immune cells to eliminate cancer cells through genetic manipulation of human immune cells.
Contact Information
Website
www.curocellbtx.comCorporate Office
- 11 Gukje Science 16-ro
- Yuseong-gu
- Daejeon, Yuseong-gu 34002
- South Korea
Corporate Office
- 11 Gukje Science 16-ro
- Yuseong-gu
- Daejeon, Yuseong-gu 34002
- South Korea
Curocell Stock Performance
As of 13-Nov-2026, Curocell’s stock price is $16.71. Its current market cap is $254M with 15.2M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $16.71 | $17.02 | $14.19 - $44.85 | $254M | 15.2M | 29.5K | -$2.42 |
Curocell Financials Summary
As of 30-Jun-2026, Curocell has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 327,618 | 466,729 | 309,456 | 387,457 |
| EBITDA | (27,827) | (25,364) | (22,161) | (17,702) |
| Net Income | (35,496) | (32,537) | (28,026) | (22,620) |
| Total Assets | 106,680 | 76,194 | 48,895 | 81,455 |
| Total Debt | 39,111 | 39,361 | 25,323 | 33,304 |
Curocell Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Curocell Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Curocell Patents
Curocell Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026161764-A1 | Membrane-anchored cytokine fusion proteins and uses thereof | Pending | 24-Jan-2025 | ||
| WO-2025220805-A1 | Novel anti-cd5 chimeric antigen receptor and use thereof | Pending | 18-Apr-2024 | ||
| WO-2025220804-A1 | Novel antibody against cd5 and uses thereof | Pending | 18-Apr-2024 | ||
| WO-2023238103-A1 | Car-t therapy for treating cancer | Inactive | 10-Jun-2022 | ||
| JP-2023518686-A | Antibodies and chimeric antigen receptors specific for bcma | Active | 13-Mar-2020 | C07K16/2878 |
Curocell Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Curocell Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Curocell Investments (1)
Curocell’s most recent deal was a Later Stage VC with NOBO Medicine for . The deal was made on 28-Jul-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| NOBO Medicine | 28-Jul-2025 | Later Stage VC | Drug Discovery |
Curocell ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Commercial Services
Industry
Rank
Percentile
Business Support Services
Subindustry
Rank
Percentile
Curocell FAQs
-
When was Curocell founded?
Curocell was founded in 2017.
-
Where is Curocell headquartered?
Curocell is headquartered in Daejeon, South Korea.
-
What is the size of Curocell?
Curocell has 140 total employees.
-
What industry is Curocell in?
Curocell’s primary industry is Drug Discovery.
-
Is Curocell a private or public company?
Curocell is a Public company.
-
What is Curocell’s stock symbol?
The ticker symbol for Curocell is 372320.
-
What is the current stock price of Curocell?
As of 13-Nov-2026 the stock price of Curocell is $16.71.
-
What is the current market cap of Curocell?
The current market capitalization of Curocell is $254M.
-
What is Curocell’s annual earnings per share (EPS)?
Curocell’s EPS for 12 months was -$2.42.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
